Keeping Track: Kadmon Chooses RTOR For Belumosudil; NDAs For Novel Imaging Agents And Liquid Anticonvulsants

 
• By Bridget Silverman

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Keeping Track Feature image
Kadmon’s product for graft-versus-host disease uses the popular Real-Time Oncology Review pilot program. • Source: Shutterstock

More from Product Reviews

More from Pink Sheet